Symptomatic Therapy & the Future

1. Symptomatic Care — the Other Half of MS Practice

Even with optimally suppressed inflammatory disease, MS patients carry a substantial burden of symptoms reflecting accumulated CNS damage. Symptomatic management determines day-to-day quality of life and is the practical ground of MS care. The approach is multidisciplinary: neurology, physiotherapy, urology, psychology, speech & swallowing, occupational therapy, social work.

• Most prevalent symptoms — fatigue (~80%), spasticity (~70%), bladder dysfunction (~75%), pain (~60%), cognitive impairment (~50%), depression (~40%), sexual dysfunction (~50%).
• Health-related quality of life declines monotonically with EDSS; symptomatic interventions add quality-adjusted life-years even where disability progression cannot be reversed.

2. Spasticity

Spasticity arises from upper-motor-neuron disinhibition with excessive stretch-reflex activity; clinically graded by the modified Ashworth scale. Management is stepwise:

• Non-pharmacologic — daily stretching, physiotherapy, treatment of triggers (UTI, constipation, pressure sores, ill-fitting orthotics).
• Baclofen — GABA_B agonist; oral 5 mg tid titrated to 60–80 mg/day; sedation, weakness; do not stop abruptly (withdrawal seizures).
• Tizanidine — α₂-adrenergic agonist; less weakness than baclofen; sedation, hypotension, transaminitis; titrate slowly.
• Dantrolene — peripheral (RyR1); useful when central side effects limit baclofen/tizanidine; hepatotoxicity.
• Gabapentin / pregabalin — off-label for tonic spasms; more often used for pain.
• Cannabinoids — nabiximols (Sativex) oromucosal spray (THC + CBD 1:1); approved in many jurisdictions for spasticity refractory to first-line therapy; modest mean reduction with responder analyses showing ~30–40% benefit subset.
• Botulinum toxin A — focal spasticity (adductor, calf, upper-limb).
• Intrathecal baclofen pump — severe lower-limb spasticity refractory to oral therapy; allows continuous CSF delivery at 1/100 oral dose, avoiding central side effects; pump complications, withdrawal emergency potential.

3. Neuropathic Pain & Paroxysmal Phenomena

• Trigeminal neuralgia — up to 5% of MS patients; pontine demyelination at the root entry zone. First-line carbamazepine, oxcarbazepine; refractory cases consider gamma-knife or microvascular decompression (less successful than in idiopathic TN).
• Lhermitte’s sign — electrical sensation down the spine on neck flexion; cervical-cord demyelination; no specific therapy.
• Painful tonic spasms — brief stereotyped spasms; carbamazepine, lacosamide, gabapentin.
• Dysaesthetic limb pain — burning, tingling; gabapentin, pregabalin, duloxetine, amitriptyline.
• Migraine — ~3× population prevalence; standard migraine prophylaxis; CGRP-monoclonals safe in MS.

4. Fatigue

MS-related fatigue is the single most common and disabling symptom; quantified with the Fatigue Severity Scale (FSS) or Modified Fatigue Impact Scale (MFIS). It is multifactorial: central inflammatory, sleep-related, depressive, deconditioning, heat sensitivity (Uhthoff). Management:

• Treat depression, sleep disorders (RLS, OSA, nocturia), anaemia, hypothyroidism.
• Aerobic exercise — most evidence-supported intervention.
• Cognitive behavioural therapy — FACETS programme.
• Cooling — pre-cooling vests for heat-sensitive patients.
• Amantadine — modest effect; the TRIUMPHANT-MS trial (Nourbakhsh et al., Lancet Neurol 2021) showed amantadine, modafinil and methylphenidate were no better than placebo for MS fatigue at 6 weeks — tempering enthusiasm for these agents.
• Modafinil / armodafinil — second-line; evidence of efficacy is modest.

5. Neurogenic Bladder

• Detrusor overactivity — urgency, frequency, urge incontinence; antimuscarinics (oxybutynin, tolterodine, solifenacin), β₃-agonist mirabegron.
• Detrusor-sphincter dyssynergia — incomplete emptying; alpha-blockers, intermittent self-catheterisation.
• Refractory overactivity — intradetrusor botulinum toxin A; sacral neuromodulation.
• Nocturia — desmopressin in selected patients (monitor sodium).
• Recurrent UTI is a major cause of pseudo-relapse; antibiotic stewardship, prophylactic methenamine, urology referral as needed.

Other autonomic / pelvic symptoms — sexual dysfunction (sildenafil, addressing depression and nocturnal spasms), constipation (fibre, osmotic laxatives, bisacodyl), anal incontinence (biofeedback, sacral nerve stimulation) — are addressed similarly with multidisciplinary input.

6. Mobility — Dalfampridine

Dalfampridine (Ampyra; 4-aminopyridine, fampridine) is a non-selective voltage-gated K⁺ channel blocker that prolongs action-potential duration in demyelinated axons, compensating for K_v1.1/1.2 channel exposure at the juxtaparanode (Part II). Pivotal trial: Goodman et al., Lancet 2009. ~35% of patients are «timed-25-foot-walk responders» with a ~25% speed gain. Seizure risk at higher doses; renal dose adjustment; not for patients with seizure history.

• Other mobility interventions: ankle-foot orthoses, functional electrical stimulation (peroneal stimulators), aerobic and resistance training, gait training.
• Falls reduction: home assessment, vitamin D, balance training; falls are a major source of fractures and morbidity.

7. Cognition & Mood

Cognitive impairment in MS preferentially affects information-processing speed (Symbol Digit Modalities Test), verbal learning, executive function. Independently predicts unemployment and progression. No DMT specifically targets cognition, though high-efficacy DMTs that suppress inflammation reduce cognitive decline indirectly. Cognitive rehabilitation, exercise, sleep optimisation are mainstays. Cross-reference Alzheimer’s for cognitive-domain frameworks.

• Depression — ~40% lifetime prevalence; SSRIs first-line; CBT effective; pseudobulbar affect treated with dextromethorphan-quinidine.
• Anxiety — commonly co-occurs with depression; same management.
• Suicide risk — ~2× population rate; screen actively, especially around diagnosis.

8. Remyelination Strategies

No licensed remyelinating drug exists. Conceptually, oligodendrocyte progenitor cells persist in adult MS brain and can produce new myelin, but their differentiation is blocked in chronic lesions. The therapeutic goal is to overcome this block.

• Clemastine — an antihistamine repurposed after a UCSF screen identified it as a pro-myelinating agent (Mei et al.). The ReBUILD trial (Green et al., Lancet 2017) in chronic MS optic neuropathy showed shortened P100 latency — the first positive remyelination signal in humans. The follow-up RECOVER trial in acute optic neuritis also showed signal.
• Opicinumab (anti-LINGO-1) — LINGO-1 is a negative regulator of oligodendrocyte differentiation. Phase II RENEW (acute ON) and SYNERGY (RRMS adjunct) trials gave mixed signals; the phase II AFFINITY trial failed in 2020, ending development.
• Bexarotene — RXR agonist; phase II showed MRI signal but tolerability poor.
• Metformin + clemastine — rejuvenation hypothesis; phase II ongoing.
• Anti-Sema6A, anti-NgR1 — preclinical.
• High-dose biotin (MD1003) — promising in phase IIb but failed phase III SPI2 (Cree et al., Lancet Neurol 2020).

The recurring lesson: protective, not regenerative, effects appear achievable in the inflammatory phase, but true remyelination of chronic lesions is harder. Trial endpoints (visual evoked potentials, magnetisation transfer ratio, OCT) have improved, but no agent has yet shown convincing clinical benefit attributable to remyelination per se.

9. EBV Vaccine and CAR-T B-Cell Depletion

The EBV-causal hypothesis (Part III) opened two therapeutic frontiers:

• EBV vaccine — conceptually the first true MS prevention strategy. Moderna mRNA-1189 is in phase I; the design includes gp350, gp42, gH/gL, and gB antigens. A 50% efficacy at preventing primary EBV infection in adolescence would, on the basis of the Bjornevik 2022 effect size, halve lifetime MS risk in vaccinated cohorts.
• EBV-specific cytotoxic T cells (autologous adoptive transfer) — ATA188 (Atara) reached phase II in progressive MS with safety and signal of EDSS improvement; phase III planned.
• EBNA-1 small-molecule inhibitors — preclinical; would aim to suppress latent EBV reactivation.

CAR-T B-cell depletion — chimeric antigen receptor T cells targeting CD19 or CD20 produce far deeper and more durable B-cell depletion than monoclonal antibodies, reaching CNS-resident B cells. Initial reports in autoimmune disease (Mackensen et al., Nat Med 2022 in SLE) prompted parallel programmes in MS:

• Anti-CD19 CAR-T (KYV-101, autologous) entered phase I MS trials in 2023.
• Hypothesis: deep, intrathecal B-cell depletion could rewire the immune system and induce sustained drug-free remission.
• Risks: cytokine release syndrome, ICANS neurotoxicity, prolonged hypogammaglobulinaemia, manufacturing complexity.

10. Autologous Haematopoietic Stem-Cell Transplantation & Cell Therapy

Autologous haematopoietic stem-cell transplantation (AHSCT) uses chemotherapy (cyclophosphamide, BCNU, anti-thymocyte globulin) to ablate the immune system, followed by reinfusion of the patient’s own CD34⁺ stem cells. The intent is an immune «reset» with drug-free remission.

• MIST trial (Burt et al., JAMA 2019) — AHSCT vs DMT in active RRMS; AHSCT superior to continued DMT for time to disability progression; ~5-year drug-free remission rates >70%.
• Indications — highly active RRMS with breakthrough on high-efficacy DMT; centre-experienced delivery.
• Mortality — modern non-myeloablative regimens carry < 0.5% transplant-related mortality.
• RAM-MS, BEAT-MS trials are randomising AHSCT vs anti-CD20 / alemtuzumab in 2024–2026 readouts.

Mesenchymal stem-cell therapy — MSCs have immunomodulatory and trophic effects but consistent efficacy in MS has been elusive. Phase II MESEMS trial (multicentre, Uccelli et al., Lancet Neurol 2021) did not show a primary-endpoint benefit on cumulative MRI activity.

Oligodendrocyte progenitor / iPSC therapy — preclinical; faces challenges of cell delivery, immune rejection, and long-term integration. The first phase I trials in progressive MS may emerge late in this decade.